Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

Abstract

Trusted evidence. Informed decisions. Better health.

Bending the Cost Curve in Cancer Care

“…Hematopoietic colonystimulating factors (CSFs) are critical to some aspects of modern chemotherapy, such as dose-dense chemotherapy, induction therapy in leukemia, and intense therapy for lymphoma. 23 Yet the expense is tremendous and the clinical benefit smaller than hoped; for instance, survival is not improved by using CSFs in two of the most chemotherapy- sensitive cancers, lymphoma 24 and small-cell lung cancer. 25 …”

Sepsis in standard care: patients’ characteristics, effectiveness of antimicrobial therapy and patient outcome—a cohort study

“…Further, patients with a malignant disease, more frequently suffered from SIRS or bacteremic/fungemic sepsis, but less frequently from nonbacteremic/fungemic sepsis. This finding could be based on an immunosuppression and therefore reduced ability to control a local infection [20][21][22]. Further, a malignant disease itself or antineoplastic chemotherapy are causative factors for developing a SIRS syndrome without any infection, e.g., neutropenic fever [23].…”

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

“…Of the 2 reported severe reactions, 1 was associated with an EDTA-containing formula, which was therefore changed. GM-CSF and G-CSF have comparable toxicity profile, albeit a higher rate of injection site reactions with the use of the former 19 . The absence of studies using comparable doses of G-CSF does not allow us to determine whether the reported discontinuation rate has to be considered high.…”